Forskning
Udskriv Udskriv
Switch language
Bispebjerg Hospital - en del af Københavns Universitetshospital
Udgivet

Exposure to Tramadol During Early Pregnancy and Risk of Spontaneous Abortion or Major Congenital Malformations

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  1. Risk of Adverse Pregnancy Outcome After Paternal Exposure to Methotrexate Within 90 Days Before Pregnancy

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Exposure to Selective Serotonin Reuptake Inhibitors in Early Pregnancy and the Risk of Miscarriage

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  3. Association between maternal weight gain and birth weight

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  4. Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  1. Short-term mortality following tramadol poisonings in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Mirtazapine exposure in pregnancy and fetal safety: A nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  3. Systemic DNA and RNA damage from oxidation after serotonergic treatment of unipolar depression

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  4. Drug use in patients with short bowel syndrome and intestinal failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

Vis graf over relationer

OBJECTIVE: To investigate whether exposure to tramadol during early pregnancy is associated with an increased risk of spontaneous abortion or major congenital malformations.

METHODS: The study is a nationwide cohort study including all registered pregnancies in Denmark between January 1, 1997, and December 31, 2016. The Danish National Prescription Register was used to identify maternal exposure to tramadol. Pregnancies with maternal exposure to tramadol were matched with pregnancies without maternal exposure to tramadol in a ratio of up to 1:4 using propensity scoring. The primary outcomes were spontaneous abortion and major congenital malformations. Cox proportional hazards regression was used to estimate the hazard ratios (HRs) of spontaneous abortion, and log binominal models were used to estimate the relative risk ratios (RRs) of major congenital malformations.

RESULTS: A total of 36,467 (tramadol exposure n=7,310) and 18,907 (tramadol exposure n=3,796) pregnancies were included in the analyses of spontaneous abortion and major congenital malformations, respectively. Spontaneous abortion occurred in 893 (12.2%) pregnancies with maternal exposure to tramadol and in 3,471 (11.9%) pregnancies without maternal exposure to tramadol (HR 1.06, 95% CI 0.99-1.14). A major congenital malformation occurred in the offspring of 151 (4.0%) pregnancies with maternal exposure to tramadol, compared with 579 (3.8%) in pregnancies without maternal exposure to tramadol (RR 1.04, 95% CI 0.87-1.24).

CONCLUSION: Exposure to tramadol during early pregnancy does not appear to be associated with an increased risk of spontaneous abortion or major congenital malformations.

OriginalsprogEngelsk
Artikelnummer0000000000004714
TidsskriftObstetrics and Gynecology
Vol/bind139
Udgave nummer4
Sider (fra-til)545-553
Antal sider9
ISSN0029-7844
DOI
StatusUdgivet - apr. 2022

Bibliografisk note

Copyright © 2022 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.

ID: 75583539